Facial reconstruction

Search LJMU Research Online

Browse Repository | Browse E-Theses

A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment

Alexander-White, C, Bury, D, Cronin, MTD, Dent, M, Hack, E, Hewitt, NJ, Kenna, G, Naciff, J, Ouedraogo, G, Schepky, A, Mahony, C and Europe, C (2022) A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment. Regulatory Toxicology and Pharmacology. ISSN 0273-2300

[img]
Preview
Text
10 step read-across accepted version.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB) | Preview

Abstract

This paper presents a 10-step read-across (RAX) framework for use in cases where a threshold of toxicological concern (TTC) approach to cosmetics safety assessment is not possible. RAX builds on established approaches that have existed for more than two decades using chemical properties and in silico toxicology predictions, by further substantiating hypotheses on toxicological similarity of substances, and integrating new approach methodologies (NAM) in the biological and kinetic domains. NAM include new types of data on biological observations from, for example, in vitro assays, toxicogenomics, metabolomics, receptor binding screens and uses physiologically-based kinetic (PBK) modelling to inform about systemic exposure. NAM data can help to substantiate a mode/mechanism of action (MoA), and if similar chemicals can be shown to work by a similar MoA, a next generation risk assessment (NGRA) may be performed with acceptable confidence for a data-poor target substance with no or inadequate safety data, based on RAX approaches using data-rich analogue(s), and taking account of potency or kinetic/dynamic differences.

Item Type: Article
Uncontrolled Keywords: 1115 Pharmacology and Pharmaceutical Sciences
Subjects: H Social Sciences > HD Industries. Land use. Labor > HD61 Risk Management
R Medicine > RM Therapeutics. Pharmacology
Divisions: Pharmacy & Biomolecular Sciences
Publisher: Elsevier BV
Date Deposited: 05 Jan 2022 12:07
Last Modified: 04 Jan 2023 00:50
DOI or ID number: 10.1016/j.yrtph.2021.105094
URI: https://researchonline.ljmu.ac.uk/id/eprint/15970
View Item View Item